Hayder Saeed, MD, Michael C

Slides:



Advertisements
Similar presentations
Diagnosis and Management of Acute Closed Angle Glaucoma after Autologous Hematopoietic Stem Cell Transplant  Tori Holmes, FNP-BC, Hayley Klein Chopra,
Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 
Amifostine Reduces High-Dose Melphalan Induced Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplant (HCT) for Plasma Cell Myeloma  Vinita.
Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease  Shuichiro Takahashi, MD, Daigo Hashimoto,
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 
Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant  Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,
How to Treat MDS without Stem Cell Transplantation
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.
Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant  Koji Sasaki, MD, Qaiser Bashir, MD, Nina Shah,
Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.
A Response Adapted Approach to Induction Treatment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation  Gunjan L. Shah,
Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,
Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation  Filippo Milano, MD, PhD, Brent.
Acute Graft-Versus-Host Disease in the Setting of T Cell Depletion: Validation of a New Agvhd Risk Score  Hayder Saeed, MD, Stacey Slone, MS, Swati Yalamanchi,
Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,
CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.
Analysis of the Prognostic Effect of Peripheral Blood Lymphocyte and Monocyte Count after Autologous Hematopoietic Stem Cell Transplant in Refractory/Relapsed.
Let Them Eat! Comparing a Neutropenic Diet to a Food Safety Based Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)  Cynthia.
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Previously Treated Germ Cell Tumors: A Single-Center Experience  Zachariah DeFilipp,
Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH 
Early Soluble ST2 Elevation Predicts Future Left Ventricular Systolic Dysfunction after Stem Cell Transplant  Christopher E. Dandoy, MD, MSc, Thomas D.
Treatment of Severe Mucositis Pain with Oral Ketamine Mouthwash
Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model  Justin N. Baker,
Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous.
Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection  Ron Mihelic,
Biology of Blood and Marrow Transplantation
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse  Zeyad Kanaan, MD, William Tse, MD, FACP 
Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia  Richard Mitchell, Todd Defor, John E. Wagner,
Graft-Versus-Host Disease Targets Granulosa Cell of Ovarian Follicle and Causes Infertility after Allogeneic Hematopoietic Stem Cell Transplantation 
Patient Self-Perceived Burden and Caregiver Burden in Recipients of Hematopoietic Stem Cell Transplantation: A Longitudinal Study Examining Gender Differences 
Eltrombopag Treatment for Primary and Secondary Thrombocytopenia Post Allogeneic and Autologous Stem Cell Transplantation is Effective and Safe  Shahram.
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L
Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution!  Anant Vatsayan, MD, Linda.
GVHD Prophylaxis with Post-Transplant High Dose Cyclophosphamide: Impact on Engraftment, Treatment-Related Mortality and Resource Utilization  Nasheed.
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Infection Prevention - Visitors and the Best of Intentions
Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.
Early Results of Phase II Study Using OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HCT-TMA)  Samer.
Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience  Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.
Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.
Myeloid Derived Suppressor Cells (MDSC)-like Acute Myeloid Leukemia (AML) Cells Are Associated with Resistance to Cytotoxic Effects of Autologous (Auto)
Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant  Ahmad Hatem Mattour,
ASBMT and CBMTG Release Choosing Wisely BMT Recommendations
Gerard Socié, K. Scott Baker, Smita Bhatia 
What is quality in a transplant program?
September Mitchell, BSN, MHI, RN, CHTC, OCN, Sarah L
Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation
Outcomes of Salvage Second Autologous Stem Cell Transplantation for Relapsed/Refractory Multiple Myeloma in the Era of Modern Therapy  Emily Case Ayers,
Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV?  Marie von Lilienfeld-Toal, MD, Maria Gilleece,
Blood and Marrow Transplant Handbook
Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.
Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation  Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.
Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy 
Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.
Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Heather A. Himburg, PhD, Liman Zhao, Jenny Kan, John P. Chute, M.D. 
Treatment versus Transplant for Challenging Hematologic Disorders
IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation  Nikhil Dole, Nathan Luebbering, Nicholas.
In Memoriam: E. Donnall Thomas
Cerebral Venous Thrombosis after Autologous Stem Cell Transplantation
Presentation transcript:

Oxidative Stress Following High Dose Chemotherapy with Autologous Stem Cell Transplant  Hayder Saeed, MD, Michael C. Alstott, Mihail Mitov, D Allan Butterfield, PhD, Emily Van Meter Dressler, PhD, Swati Yalamanchi, MD, John Hayslip, MD, Gregory Monohan, MD  Biology of Blood and Marrow Transplantation  Volume 22, Issue 3, Pages S131-S132 (March 2016) DOI: 10.1016/j.bbmt.2015.11.463 Copyright © 2016 Terms and Conditions

Figure 1 Changes in PC, NT and HNE from baseline in the BEAM group, P value for significant from pretransplant level only significant P values are shown. Biology of Blood and Marrow Transplantation 2016 22, S131-S132DOI: (10.1016/j.bbmt.2015.11.463) Copyright © 2016 Terms and Conditions

Figure 2 changes in PC, NT and HNE in the Melphalan group, P value for significance from pretranssplant level, only significant P values are shown. Biology of Blood and Marrow Transplantation 2016 22, S131-S132DOI: (10.1016/j.bbmt.2015.11.463) Copyright © 2016 Terms and Conditions